Probiotics as vehicles for vaccine administration

我们已经通过使用SIV GAG蛋白作为模型抗原测试了这种实验方法。在指定载体上制备重组GAG蛋白，并与嗜酸乳杆菌混合。观察GAG蛋白与细菌的结合，并通过胃灌胃给药+/- SIV GAG蛋白的微生物3周。免疫2或3周后，4只治疗小鼠中有2只出现了强烈的抗体应答。基于这种阳性反应，我们正在开发重组肿瘤抗原融合蛋白，即TARP和K-ras，以评估这些抗原在乳杆菌表面时宿主对这些抗原的反应。在创建合适的重组后，我们将确定小鼠是否可以免受KRAS驱动的肿瘤的保护。

We have tested this experimental approach by using the SIV GAG protein as a model antigen. Recombinant GAG protein was prepared in the designated vector and the fusion protein obtained was mixed with Lactobacillus acidolphilus. Binding of the GAG protein to the bacteria was observed and mice were administered the microorganisms +/- the SIV GAG protein via stomach gavage over a 3 week period. A strong antibody response was observed in 2 of 4 treated mice after 2 or 3 weeks of immunization. Based on this positive response, we are developing recombinant tumor antigen fusion proteins, i.e. TARP and K-ras, in order to evaluate the host response to these antigens when presented on the surface of Lactobacillus. Upon creation of the appropriate recombinant we will determine if the mice can be protected from KRAS driven tumors.